On Monday, Werewolf Therapeutics Inc (NASDAQ: HOWL) was -4.79% drop from the session before settling in for the closing price of $0.6. A 52-week range for HOWL has been $0.56 – $2.38.
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.76%. When this article was written, the company’s average yearly earnings per share was at 7.24%. With a float of $39.30 million, this company’s outstanding shares have now reached $47.27 million.
Werewolf Therapeutics Inc (HOWL) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Werewolf Therapeutics Inc stocks. The insider ownership of Werewolf Therapeutics Inc is 19.18%, while institutional ownership is 29.83%. The most recent insider transaction that took place on Jan 12 ’26, was worth 33,619. In this transaction Director of this company sold 58,980 shares at a rate of $0.57, taking the stock ownership to the 2,309,869 shares. Before that another transaction happened on Jan 09 ’26, when Company’s Director sold 24,678 for $0.61, making the entire transaction worth $15,054. This insider now owns 2,368,849 shares in total.
Werewolf Therapeutics Inc (HOWL) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.46 earnings per share (EPS) during the time that was less than consensus figure (set at -0.31) by -0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.89% during the next five years compared to -20.76% drop over the previous five years of trading.
Werewolf Therapeutics Inc (NASDAQ: HOWL) Trading Performance Indicators
You can see what Werewolf Therapeutics Inc (HOWL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.47 in one year’s time.
